Medical Devices

With a massive late-stage pipeline and deep pockets, the biotech aims to defeat elusive cancer targets, but soaring costs raise the stakes for pivotal trials.

Mahzi Therapeutics has dosed its first patient in a landmark study, offering a potential breakthrough for a rare and severe neurogenetic disorder.

Celebrating its 40th anniversary, the Ricordi® Chamber not only transformed diabetes research but now serves as the foundation for the future of cell therapy.

Amid a surge in MedTech M&A, Piper Sandler appoints 25-year veteran Aamer Naseer to steer its life sciences outsourcing and B2B technology groups.

A new partnership will bring Gentuity's high-resolution intravascular imaging to more U.S. cath labs, promising a new era of precision for heart procedures.

Cara Medical's AI-powered CARA System gets FDA approval, promising to revolutionize complex heart procedures with 3D visualization of the conduction system.

Curanex Pharmaceuticals hits a key manufacturing milestone for Phyto-N, a botanical drug with a 30-year history, advancing its quest for FDA approval.

With promising preclinical data and Australian trial approval, Kivu’s KIVU-305 aims to overcome past failures in targeting aggressive solid tumors.

New subgroup data from ITM's COMPETE trial could refine treatment for a tough-to-treat cancer and bolster the company's position in the radiopharma market.

As Evolus presents at a key healthcare conference, investors watch to see if its new filler line and digital strategy can deliver on bold promises.

Investors sue Corcept Therapeutics, claiming the company hid FDA warnings about its key drug, relacorilant, before a 50% stock price collapse.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

Medtech giant reveals its 'Magnificent Seven' innovations and new data, with Chief Movement Officer Arnold Schwarzenegger leading the charge at AAOS 2026.

With $400M in 2025 sales, Immunocore now leverages its KIMMTRAK success to fund a high-stakes pivot into broader cancers, HIV, and autoimmune disease.

With the appointment of TechTarget co-founder Don Hawk, Life Science Connect is set to import a proven B2B intent data playbook into the life sciences.

A landmark partnership aims to bring precision cancer therapy, or Theranostics, to millions in underserved nations, backed by a major WHO resolution.

By fitting into existing hospital rooms, Mevion's newly CE-Marked proton therapy system aims to slash costs and expand access to advanced cancer treatment.

New FDA-cleared Persona PLUS technology promises to increase plasma yields per donor, tackling the growing global demand for life-saving therapies.

Promising trial data for onvansertib offers new hope for colorectal cancer patients, yet leadership changes and financial hurdles cloud the path forward.

The life sciences giant's significant dividend hike underscores its robust financial health and commitment to growth, even as it pursues major acquisitions.